Abstract Background: At present, clinical decision making and drug discovery are based on an incomplete picture of tumor biology. Deep learning (DL) has demonstrated the ability to infer oncogenic molecular signatures from data acquired during standard oncologic care (e.g., histopathology [H 2025 Dec 9-12; San Antonio, TX. Philadelphia (PA): AACR; Clin Cancer Res 2026;32(4 Suppl):Abstract nr PS3-04-15.
Goncalves et al. (Tue,) studied this question.